HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Hormone refractory prostate cancer — Clinical Guidelines

Overview

Hormone refractory prostate cancer (HRPC) refers to advanced prostate cancer that no longer responds to initial androgen deprivation therapy, necessitating alternative treatment strategies to manage disease progression and symptoms.

Diagnosis

Confirmation of rising PSA levels despite ongoing androgen deprivation therapy 7.

Presence of metastatic disease on imaging studies (bone scans, CT, MRI) 7.

Assessment of clinical symptoms and functional status 8.

Management

First-line treatments:

- Androgen receptor signaling inhibitors (ARSIs) such as abiraterone, enzalutamide, or apalutamide 2. - Chemotherapy with docetaxel (though evidence varies) 12.

Adjunctive treatments:

- Radium-223 for symptomatic bone metastases to alleviate pain 6. - Strontium-89 for palliation of bone pain 11. - Hydrocortisone with or without mitoxantrone (M+H regimen) for symptom management 12.

Considerations for adverse events:

- Monitoring and managing side effects of GnRH agonists like leuprolide and goserelin 1.

Special Populations

Elderly patients: Increased focus on medication burden and acute care utilization due to polypharmacy 2.

Quality of life: Balancing life-prolonging treatments with symptom management to maintain QoL in palliative care settings 8.

Key Recommendations

Initiate androgen receptor signaling inhibitors (e.g., abiraterone, enzalutamide) as first-line therapy for metastatic hormone refractory prostate cancer 2 (Evidence: Strong).

Consider Radium-223 for patients with symptomatic bone metastases to improve bone pain palliation 6 (Evidence: Moderate).

Evaluate the use of hydrocortisone with or without mitoxantrone for symptom management in patients with limited treatment options 12 (Evidence: Weak).

Regularly assess and manage medication burden in older patients to reduce acute care utilization 2 (Evidence: Moderate).

Prioritize quality of life and symptom control alongside disease management in palliative care settings 8 (Evidence: Expert opinion).

References

1 Zhou F, Yang M, Ji W, Ma J, Ren N, Ren X. Evaluation of adverse event profiles for leuprolide and goserelin: Insights from the FDA adverse event reporting system following STROBE guidelines. Medicine 2026. link 2 Liu MA, Raghunathan R, Runcie K, Wooster M, Wang S, Wright JD et al.. Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors. Cancer 2025. link 3 Valeri A, Nguyen TA. Research on texture images and radiomics in urology: a review of urological MR imaging applications. Current opinion in urology 2023. link 4 Salib A, Halpern E, Eisenbrey J, Chandrasekar T, Chung PH, Forsberg F et al.. The evolving role of contrast-enhanced ultrasound in urology: a review. World journal of urology 2023. link 5 Emons G. Hormone-Dependent Cancers: Molecular Mechanisms and Therapeutical Implications. Cells 2022. link 6 Frantellizzi V, Lazri J, Pontico M, Pani A, De Vincentis G. Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2020. link 7 Yu EY, Gillessen S, Mottet N. What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations. European urology focus 2019. link 8 Holm M, Doveson S, Lindqvist O, Wennman-Larsen A, Fransson P. Quality of life in men with metastatic prostate cancer in their final years before death - a retrospective analysis of prospective data. BMC palliative care 2018. link 9 Sammon JD, McKay RR, Kim SP, Sood A, Sukumar S, Hayn MH et al.. Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. Urology 2015. link 10 Heintzelman NH, Taylor RJ, Simonsen L, Lustig R, Anderko D, Haythornthwaite JA et al.. Longitudinal analysis of pain in patients with metastatic prostate cancer using natural language processing of medical record text. Journal of the American Medical Informatics Association : JAMIA 2013. link 11 Turner SL, Gruenewald S, Spry N, Gebski V. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. British journal of cancer 2001. link 12 Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V et al.. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999. link 13 Carroll KK. Experimental evidence of dietary factors and hormone-dependent cancers. Cancer research 1975. link

Hormone refractory prostate cancer